Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
Danish biotechnology company Genmab has experienced a significant stock surge, with shares nearly doubling over the last three months. This momentum follows three successful Phase 3 clinical trials in October for its cancer treatments: petosemtamab (head and neck cancer), Rina-S (ovarian cancer), and Epkinly (lymphoma). The results have bolstered investor confidence in Genmab's strategic shift from a royalty-based model to an owner-operator of its own medicines. Specifically, the combination of petosemtamab and Merck's Keytruda showed a 50% reduction in death risk for head and neck cancer patients. Analysts suggest petosemtamab could reach peak annual sales of up to $7 billion if expanded into locally advanced disease. The company is leveraging massive royalty streams from established drugs like Johnson & Johnson's Darzalex to fund this transition toward high-margin, proprietary commercialization.
Tickers: $ABBV $GMAB $JNJ $MRK $NVS
Topics: Cancer treatment Drug development strategy Phase 3 clinical trials Stock price surge